Chimeric Therapeutics Limited · ASX:CHM
Chimeric Therapeutics — Investor Presentation (January 2024)
41 slides from Chimeric Therapeutics's investor presentation, Jan 18, 2024
Slide 1: Bringing the Promise of Cell Therapy to Life
BRINGING THE For personal use only PROMISE OF CELL THERAPY TO LIFE Corporate Update January, 2024
Slide 2: Disclaimer
DISCLAIMER For personal use only Certain statements contained in this presentation, including, information or studies to be completed or provided prior to their without limitation, statements containing the words “believes,” approval of our products. “plans,” “expects,” “anticipates,” and words of s
Slide 3: Corporate Profile
CHIMERIC THERAPEUTICS (ASX: CHM) CORPORATE PROFILE “We can now conclude For personal use only that CAR-T cells can Market Information CURE Share Price (AUD) $0.029 patients with leukemia” (January 17, 2024) $0.025- Dr Carl June, MD 52 Week Range (AUD) Richard W. Vague Professor in Immunotherapy Dire
Slide 4: Advancing Clinical Development with Positive Phase 1 Results
ADVANCING 2 CLINICAL TRIALS CLINICAL DEVELOPMENT WITH POSITIVE PHASE 1 RESULTS • 4 clinical trials in solid tumours and blood cancers in 2024 For personal use only • Multiple clinical catalysts in the • Positive CHM 1101 Phase next 12-18 months 1A data in Recurrent Brain Bringing Cancer the Promise
Slide 5: Key Clinical Catalysts Across the Platform Technologies
KEY CLINICAL CATALYSTS ACROSS THE 3 PLATFORM TECHNOLOGIES 2023 Clinical Achievements 2024 Clinical Milestones For personal use only • Ph. 1A Dose Escalation Complete in GBM • Ph. 1B Dose Expansion Initiation in GBM CHM 1101 • Ph. 1A Positive Preliminary Data in GBM • Ph. 1B Preliminary Dose Expansio
Slide 6: Chimeric: Novel Platform Technologies
CHIMERIC: 3 NOVEL PLATFORM TECHNOLOGIES CHM 1101 CHM 2101 CHM 0201 For personal use only (CLTX CAR T) (CDH17 CAR T) (CORE NK) 2020 2021 2022 Potentially best in class NK cell platform First in class CLTX CAR T for brain First in class CDH17 CAR T 2022 and solid tumours for blood cancers cancer and o
Slide 7: CHM 1101 (CLTX CAR T): First in Class CAR T Optimized for Solid Tumors
CHM 1101 (CLTX CAR T) FIRST IN CLASS CAR T OPTIMIZED FOR SOLID TUMORS NOVEL OPTIMIZED For personal use only TARGET CONSTRUCT CLTX ü Novel, natural toxin Chlorotoxin ü First in class Chlorotoxin (CLTX) binder (CLTX) binder with a compact, stable, binder targets MMP2 peptide structure ü MMP2 is a biol
Slide 8: Positive Phase 1A Clinical Data in Recurrent, Late-Stage Brain Cancer
8 POSITIVE PHASE 1A CLINICAL DATA IN RECURRENT, LATE-STAGE BRAIN CANCER For personal use only DISEASE SURVIVAL SAFETY CONTROL RATE ~10 months Generally, well tolerated 55% Median survival in patients that achieved disease control • No Dose Limiting Toxicities Disease Control Rate (DCR) in heavily pr
Slide 9: How Is Glioblastoma (GBM) Treated Today?
HOW IS GLIOBLASTOMA (GBM) TREATED TODAY? TREATMENT BECOMES MORE CHALLENGING AS THE DISEASE PROGRESSES Treatment in subsequent lines of therapy Treatment in front line is the standard becomes progressively more difficult with For personal use only of care combination of surgery, reduced survival expe
Slide 10: CHM 1101 Phase 1A Patient Demographics
CHM 1101 PHASE 1A PATIENT DEMOGRAPHICS TREATING 4TH LINE PATIENTS For personal use only Median 57 years 46% Age Range 37-73 years Male 55% of patients received CHM 1101 as Sex Female 45% 4th line therapy Caucasian 73% Black 9% Race Asian 9% CHM 1101 Patients Hispanic 9% 0 18% 2nd Line 3rd Line 4th L
Slide 11: CHM 1101 Results in Context
CHM 1101 RESULTS IN CONTEXT 55% DISEASE CONTROL IN LATE LINE PATIENTS For personal use only CHM 1101 2nd Line 4th Line 2nd Line Treatment1 Treatment Treatment2 20% 55% 37% Disease Control1 Disease Control Disease Control2 CHM 1101 was studied in median 4th line patients and demonstrated a Disease Co
Slide 12: Survival Expectations for Patients with Recurrent GBM
SURVIVAL EXPECTATIONS FOR PATIENTS WITH RECURRENT GBM Therapy Line of Therapy Overall Survival For personal use only SURGERY 2nd Line1 5.75 months1 ~7 months TUMOUR TREATING FIELDS 3rd Line2 6.6 months2 survival APPROVED THERAPIES demonstrated BEVACIZUMAB 2nd Line3 7.75 months3 from first TEMOZOLOMI
Slide 13: CHM 1101 Phase 1A Survival
CHM 1101 PHASE 1A SURVIVAL ~10 MONTH SURVIVAL IN PATIENTS WHO ACHIEVED DISEASE CONTROL Overall Survival (Months) For personal use only Patient 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 A 14+ months B In two patients who C achieved disease control D 9.9 months E Median overall survival F in
Slide 14: CHM 1101 Phase 1A Patients with Long Term Survival
CHM 1101 PHASE 1A PATIENTS WITH LONG TERM (14+ MONTHS ) SURVIVAL For personal use only CHM 1101 Dose: 44 X 106 CHM 1101 Dose: 88 X 106 Line of Therapy: 3rd Line of Therapy: 4th OVERALL ONGOING SURVIVAL SURVIVAL 19 14.4+ months months 10 79 10 70 Infusions Days to Relapse Infusions Days to Relapse
Slide 15: CHM 1101 Phase 1A Safety
CHM 1101 PHASE 1A SAFETY A MANAGEABLE SAFETY PROFILE AT ALL DOSE LEVELS Grade 3 (serious) For personal use only non-hematological events were not considered treatment No Dose No Cytokine No Tumour related: Limiting Release Lysis • Cerebral Edema X3* Toxicities Syndrome Syndrome • Adrenal (DLT’s) (CR
Slide 16: CHM 1101 Next Steps
CHM 1101 NEXT STEPS ADVANCING IN PHASE 1B CLINICAL DEVELOPMENT Based upon the safety and efficacy signal demonstrated in the Phase 1A City of Hope clinical trial, CHM 1101 will advance to Dose Expansion in the Chimeric Phase 1B Clinical Trial in 2024 For personal use only
Slide 17: CHM 1101 Summary
CHM 1101 SUMMARY POSITIVE PHASE 1A DATA IN LATE STAGE GLIOBLASTOMA For personal use only ü 4th line, difficult to treat patients ü 55% Disease Control Rate ü ~10 months survival for patients that achieved disease control ü Two patients with survival beyond 14 months ü Manageable safety profile at al
Slide 18: CHM 2101 (CDH17 CAR T): First in Class CAR T Designed for GI Cancers
CHM 2101 (CLTX CAR T) FIRST IN CLASS CAR T DESIGNED FOR GI CANCERS NOVEL OPTIMIZED For personal use only TARGET CONSTRUCT ü First in class anti- Cadherin-17 ü Single domain VHH antibody binder with (CDH17) binder high affinity for human CDH17 ü CDH17 is a biologically relevant ü Highly compact, stab
Slide 19: CHM 2101: FDA IND Clearance
CHM 2101: FDA IND CLEARANCE A FIRST-IN-CLASS 3RD GENERATION CAR T FOR GASTROINTESTINAL TUMOURS For personal use only • FDA clearance for Chimeric IND for a Phase 1/ 2 clinical program in Colorectal Cancer, Gastric Cancer and Neuroendocrine Tumours CDH17 CAR T • First-in-class CAR T cell therapy lice
Slide 20: CHM 2101 (CDH17 CAR T): Potent In Vivo Efficacy
CHM 2101 (CDH17 CAR T) POTENT IN VIVO EFFICACY For personal use only CHM 1101 induced complete eradication of tumours with no relapse in seven mouse xenograft tumour models Neuroendocrine Gastric Pancreatic Tumours Cancer Cancer Source: Feng et al., Nature Cancer, 2022
Slide 21: CAR T Cells Unable to Access Normal Cells Due to Tight Junctions
CHM 2101 (CDH17 CAR T) CAR T CELLS UNABLE TO ACCESS NORMAL CELLS DUE TO TIGHT JUNCTIONS Normal Cells Cancer Cells For personal use only The tight junctions between In cancer, loss of cell polarity causes CDH17 to In normal cells, CDH17 is epithelial cells are thought to be exposed on the tumor cell
Slide 22: CHM 2101: Safety in Preclinical Models
CHM 2101: SAFETY IN PRECLINICAL MODELS DESPITE BROAD EXPRESSION OF CDH17 ON NORMAL INTESTINE, MICE TREATED WITH CHM 2101 DEMONSTARTED NO TREATMENT RELATED TOXICITY For personal use only No body weight loss No damage to normal tissue No infiltration of normal intestine by CHM 2101 cells No tissue dam
Slide 23: Phase 1A Clinical Trial in Relapse/Refractory GI Cancers
CHM 2101 (CDH17 CAR T) PHASE 1A CLINICAL TRIAL IN RELAPSE / REFRACTORY GI CANCERS For personal use only Accelerated development through a Phase 1A basket trial design with patient eligibility in 3 tumour types Upon signal confirmation, dose confirmation and expansion in tumour specific cohorts Color
Slide 24: CHM 0201
CHM 0201 Broad Encouraging For personal use only A platform applicability Phase 1A technology across 10+ Clinical Trial that can be disease Results across leveraged to multiple key areas develop endpoints in including multiple new Acute Myeloid blood cancers therapies Leukemia and BEST-IN-CLASS and
Slide 25: CHM 0201: Completed Phase 1A
CHM 0201: COMPLETED PHASE 1A ENCOURAGING CLINICAL OUTCOMES WITH A 24+ MONTH ONGOING COMPLETE RESPONSE For personal use only PATIENT #8 24+ MONTH ONGOING COMPLETE RESPONSE IN AML SOLID BLOOD with therapy related High-Risk MDS SAFETY PERSISTENCE EXPANSION TUMOUR CANCER EFFICACY EFFICACY CHM 0201 INFUS
Slide 26: CHM 0201 for Blood Cancers and Solid Tumours
CHM 0201 for BLOOD CANCERS AND SOLID TUMOURS ADVANCING NOVEL PHASE 1B CLINICAL COMBINATIONS For personal use only CHM 0201 + VACTO CHM 0201 + AZA/VEN Phase 1B Phase 1B ENROLLMENT CURRENTLY ONGOING ENROLLMENT PAUSED DUE TO STAFF RESOURCING FDA IND Clearance Acute Myeloid Leukemia and Acute Myeloid Co
Slide 27: CHM 1301: CLTX CAR NK Development
CHM 1301: CLTX CAR NK DEVELOPMENT LEVERAGING PORTFOLIO SYNERGIES TO BUILD UPON A A BEST-IN- CLASS NK CELL FOUNDATION For personal use only CHM 0201 CHM 1101 CHM 1301 (CORE NK) (CLTX CAR T) (CLTX CAR NK)
Slide 28: CHM 1301: CLTX CAR NK
CHM 1301: CLTX CAR NK UP TO 300% ENHANCED CELL KILLING IN TWO NEW TUMOUR TYPES CHM 1301 demonstrated ~2-3x increased potency against Ovarian and Pancreatic For personal use only cancer cells when compared to CHM 0201 Pancreatic Cancer Ovarian Cancer CHM 1301 (CLTX CAR NK) CHM 1301 (CLTX CAR NK) CHM
Slide 29: Value Proposition for Investors
VALUE PROPOSITION FOR INVESTORS For personal use only 1. 2. 3. ADVANCED, ADVANCING NAVIGATING UNDERVALUED DEVELOPMENT TO THE PORTFOLIO VALUE REALIZATION CHALLENGES Chimeric’s pipeline and Chimeric’s assets are Chimeric is responding to portfolio are highly entering Phase 1B, todays biotech environme
Slide 30: 1. Advanced, Undervalued Portfolio
1. ADVANCED, UNDERVALUED PORTFOLIO 3 Chimeric has an industry leading cell therapy portfolio with novel technology platforms in clinical stage development CHM Asset Tumour Type Discovery/ Preclinical Phase 1 Phase 2/ 3 For personal use only Recurrent/ Progressive COH Phase 1A Novel technology Gliobl
Slide 31: Chimeric: Innovation Undervalued in Today's Market
CHIMERIC: INNOVATION UNDERVALUED IN TODAYS MARKET Cell Therapy Pipeline Only 2 For personal use only Assets with No Clinical No Clinical No Clinical Positive Clinical Data Data Data Data Enrolling Clinical Trials 4 No Clinical Trials No Clinical Trials 1 Patients Treated 25+ No Patients Treated No P
Slide 32: Value Realization Opportunity Focuses on Phase 1B/2
VALUE REALIZATION OPPORTUNITY FOCUSES ON PHASE 1B/ 2 CHIMERIC IS ADVANCING DEVELOPMENT TO BIG PHARMA’S FOCUS In today's market, big pharma M&A has shifted its focus from preclinical assets to assets that are clinically de-risked with Phase1A/B data For personal use only PHASE REGULATORY As developme
Slide 33: 2. Value Realization Opportunity: Recent M&A Highlights
2. VALUE REALIZATION OPPORTUNITY FOCUSES ON PHASE 1B/ 2 RECENT M&A HIGHLIGHTS BIG PHARMA’S FOCUS ON CLINICALLY DE-RISKED ASSETS Date Acquirer / Licensee Phase of Total Deal Value For personal use only Investor Development $50M USD August 2023 1B (equity investment) $25M July 2023 1B (equity investme
Slide 34: 3. Navigating the Challenges
3. NAVIGATING THE CHALLENGES To enable clinical advancement, Chimeric has responded to the challenges of todays market with program prioritization and cash preservation while creating value through business development For personal use only
Slide 35: Chimeric Leadership Team
CHIMERIC LEADERSHIP TEAM GLOBAL EXPERTS IN CELL THERAPY DEVELOPMENT & COMMERCIALIZATION EXPERIENCE EXPERTISE PROVEN For personal use only 60+ 25+ Development 4/5 Years of Cell Of the FDA Approved Therapy Experience Programs CAR T Cell Therapies Jennifer Dr Eliot Dr Jason Dr Stephanie Kelly CHOW BOUR
Slide 36: Cellular Immunotherapy Scientific Advisory Board
CELLULAR IMMUNOTHERAPY SCIENTIFIC ADVISORY BOARD WORLD RENOWNED SCIENTISTS AND CLINICIANS For personal use only Chair of the Cellular Director, the David and Director of Translational Medical Director, Cellular Therapeutics Cross Etta Jones Center for Research, Immune Effector Immunotherapy and the
Slide 37: Positive Clinical Data in GBM and AML
3 7 POSITIVE CLINICAL DATA in GBM and AML Two assets with positive Phase 1A clinical data ADVANCING CLINICAL DEVELOPMENT For personal use only Four clinical trials in solid tumours and blood cancers in 2024 NEAR TERM MILESTONES Multiple clinical catalysts in next 12-18 months IMPACTFUL BUSINESS DEVE
Slide 38: Contact Information
CONTACT INFORMATION For personal use only Jennifer Chow Chief Executive Officer and Managing Director Chimeric Therapeutics Ltd Cell: +1 908-723-8387 jchow@chimerictherapeutics.com Paul A. Hopper Executive Chairman Chimeric Therapeutics Ltd Cell: +61 406671515 paulhopper@lifescienceportfolio.com
Slide 39: Appendix
For personal use only APPENDIX. 39
Slide 40: Glioblastoma (GBM)
GLIOBLASTOMA (GBM) MOST COMMON AND DEADLY OF ALL PRIMARY BRAIN TUMOURS WHAT IS WHO GETS WHAT ARE THE WHAT IS THE For personal use only GLIOBLASTOMA GBM? RISK FACTORS PROGNOSIS FOR (GBM)? FOR GBM? GBM? Glioblastomas (also called ~1000 new cases of GBM The exact cause of GBM Without Treatment: GBM) ar
Slide 41: CDH17: An Ideal Tumor Targeting Antigen
CDH17: AN IDEAL TUMOR TARGETING ANTIGEN KEY TO CANCER PROLIFERATION CDH17 (Cadherin-17) is an oncogenic driver of tumor formation For personal use only and cancer metastasis, most specifically in gastrointestinal tumors. Overexpression of CDH17 has been shown to be correlated with poor prognosis and
Chimeric Therapeutics — Investor Presentation (January 2024) on 6ix